Switch theme
Sign up to access all valuation multiples
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
2000
104
LTM Revenue $113M
LTM EBITDA $11.1M
$699M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Niagen Bioscience has a last 12-month revenue (LTM) of $113M and a last 12-month EBITDA of $11.1M.
In the most recent fiscal year, Niagen Bioscience achieved revenue of $99.6M and an EBITDA of $9.2M.
Niagen Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Niagen Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $113M | XXX | $99.6M | XXX | XXX | XXX |
| Gross Profit | $70.9M | XXX | $61.6M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $11.1M | XXX | $9.2M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $9.0M | XXX | $7.7M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $10.1M | XXX | $8.6M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 1, 2025, Niagen Bioscience's stock price is $10.
Niagen Bioscience has current market cap of $751M, and EV of $699M.
See Niagen Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $699M | $751M | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 1, 2025, Niagen Bioscience has market cap of $751M and EV of $699M.
Niagen Bioscience's trades at 7.0x EV/Revenue multiple, and 75.9x EV/EBITDA.
Equity research analysts estimate Niagen Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Niagen Bioscience has a P/E ratio of 74.4x.
See valuation multiples for Niagen Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $751M | XXX | $751M | XXX | XXX | XXX |
| EV (current) | $699M | XXX | $699M | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 62.7x | XXX | 75.9x | XXX | XXX | XXX |
| EV/EBIT | 77.5x | XXX | 90.4x | XXX | XXX | XXX |
| EV/Gross Profit | 9.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 74.4x | XXX | 87.8x | XXX | XXX | XXX |
| EV/FCF | 99.7x | XXX | 58.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNiagen Bioscience's last 12 month revenue growth is 22%
Niagen Bioscience's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.5M for the same period.
Niagen Bioscience's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Niagen Bioscience's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Niagen Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 62% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Niagen Bioscience acquired XXX companies to date.
Last acquisition by Niagen Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Niagen Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Niagen Bioscience founded? | Niagen Bioscience was founded in 2000. |
| Where is Niagen Bioscience headquartered? | Niagen Bioscience is headquartered in United States of America. |
| How many employees does Niagen Bioscience have? | As of today, Niagen Bioscience has 104 employees. |
| Who is the CEO of Niagen Bioscience? | Niagen Bioscience's CEO is Mr. Robert N. Fried. |
| Is Niagen Bioscience publicy listed? | Yes, Niagen Bioscience is a public company listed on NAS. |
| What is the stock symbol of Niagen Bioscience? | Niagen Bioscience trades under NAGE ticker. |
| When did Niagen Bioscience go public? | Niagen Bioscience went public in 2008. |
| Who are competitors of Niagen Bioscience? | Similar companies to Niagen Bioscience include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Niagen Bioscience? | Niagen Bioscience's current market cap is $751M |
| What is the current revenue of Niagen Bioscience? | Niagen Bioscience's last 12 months revenue is $113M. |
| What is the current revenue growth of Niagen Bioscience? | Niagen Bioscience revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Niagen Bioscience? | Current revenue multiple of Niagen Bioscience is 6.2x. |
| Is Niagen Bioscience profitable? | Yes, Niagen Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Niagen Bioscience? | Niagen Bioscience's last 12 months EBITDA is $11.1M. |
| What is Niagen Bioscience's EBITDA margin? | Niagen Bioscience's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Niagen Bioscience? | Current EBITDA multiple of Niagen Bioscience is 62.7x. |
| What is the current FCF of Niagen Bioscience? | Niagen Bioscience's last 12 months FCF is $7.0M. |
| What is Niagen Bioscience's FCF margin? | Niagen Bioscience's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Niagen Bioscience? | Current FCF multiple of Niagen Bioscience is 99.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
